News Search Results
Jan 29, 2026, 11:05 ET Slope and LabConnect Expand Partnership Momentum with Multiple API-Integrated Clinical Trials Launched in Q4 2025
slopeclinical.com.About LabConnectLabConnect is redefining central laboratory services as a technology-driven partner for pharmaceutical and biotechnology companies. Our decentralized network model provides sponsors with access to the industry's most comprehensive global testing menu,
More news about: Slope
Jan 29, 2026, 09:10 ET Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery
Biosciences®, the microbial ecology company, today announced that it has signed a development and commercialization agreement with Sacco System, a global biotechnology company specializing in the research, development and production of natural and innovative biotechnological solutions for the food, nutraceutical,
More news about: Concerto Biosciences
Jan 29, 2026, 09:00 ET bitBiome and Tojo Vikas Announce Strategic Collaboration in Sustainable Flavor & Fragrance Biomanufacturing
market knowledge, customer relationships, and long-standing expertise in ingredient commercialization, combined with bitBiome's differentiated biotechnology platform for discovering and producing novel synthetic biological solutions including enzymes, proteins, strains and ingredients.bitBiome
More news about: bitBiome
Jan 29, 2026, 09:00 ET Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy
management, with a total deal value approaching USD $120 million.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Jan 29, 2026, 08:07 ET Former FDA Economist Dr. Nikki Tavasoli Joins Ocean Tomo, a Part of J.S. Held
bans—expertise directly applicable to antitrust, intellectual property disputes, and damages quantification in healthcare, pharmaceuticals, and biotechnology.Dr. Tavasoli's Research FocusDr. Tavasoli's research blends behavioral economics, health policy, and advanced data science,
More news about: J.S. Held
Jan 29, 2026, 08:01 ET GenScript Biotech Global Forum, "Scripting Possibilities", Convened AI and Biopharma Leaders in San Francisco
"The conversations throughout the day reinforced that biotechnology is indeed at an inflection point, but they also sharpened what that means in practice," said Ray Chen, PhD, President of GenScript Life Science
More news about: GenScript Biotech Corporation
Jan 29, 2026, 08:00 ET NanoMosaic Secures FDA Advanced Manufacturing Technology (AMT) Designation for Advanced Gene Therapy Analytics
the technology's advanced capabilities to other viral and non-viral modalities".About NanoMosaicNanoMosaic is a pioneering biotechnology company that develops innovative tools and technologies for multiomic biomarker detection and analysis. The company's flagship product, the NanoMosaic
More news about: NanoMosaic
Jan 29, 2026, 07:00 ET NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
Corporate PresentationAbout NewcelX Ltd.NewcelX Ltd. (NASDAQ: NCEL) is a clinical-stage biotechnology company focused primarily on developing cell-based therapies for Type 1 Diabetes, supported by a broader platform spanning neurodegenerative and
More news about: NewcelX Ltd.
Jan 29, 2026, 06:58 ET Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
foundation for transition into the next stage of clinical development."About Innovative MoleculesInnovative Molecules GmbH is a biotechnology company based in Munich, Germany, focused on developing transformative therapies for herpes infections. Its pipeline is dedicated to advancing novel
More news about: Innovative Molecules GmbH
Jan 29, 2026, 06:54 ET Innovative Molecules Announces Completion of Phase 1 Program and Advancement to Phase 2 for Oral Adibelivir
foundation for transition into the next stage of clinical development."About Innovative MoleculesInnovative Molecules GmbH is a biotechnology company based in Munich, Germany, focused on developing transformative therapies for herpes infections. Its pipeline is dedicated to advancing novel
More news about: Innovative Molecules GmbH
Jan 29, 2026, 06:30 ET Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases
CAMBRIDGE, Mass., Jan. 29, 2026 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic
More news about: Repertoire Immune Medicines
Jan 29, 2026, 06:10 ET Sports Nutrition Market Size Expected to Reach USD 108.1 Billion by 2035, Growing at a CAGR of 7.55% | Research by Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Jan 29, 2026, 06:00 ET Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
(Nasdaq: SGMT) for exclusive rights in Greater China.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jan 29, 2026, 04:00 ET LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress
transformative year for our portfolio companies and for our fund." LifeArc Ventures invests broadly across therapeutics and tech-enabled biotechnology companies across all modalities and therapeutic areas as part of its direct investment strategy. LifeArc Ventures also runs a fund of funds strategy
More news about: LifeArc
Jan 29, 2026, 03:30 ET TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
expansionBASEL, Switzerland, Jan. 29, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus rejuvenation, today announced the appointment of Dr. Klaas P. Zuideveld, Ph.D.,
More news about: TECregen AG
Jan 28, 2026, 20:00 ET Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem
About Nona BiosciencesNona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from discovery to early clinical development and Investigator-Initiated
More news about: Nona Biosciences
Jan 28, 2026, 16:01 ET AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ: ONCY), BioNTech (NASDAQ: BNTX), MAIA Biotechnology (NYSE-A: MAIA), Acrivon Therapeutics (NASDAQ: ACRV), and ImmunityBio (NASDAQ: IBRX).
More news about: USA News Group
Jan 28, 2026, 09:03 ET GenScript is Scripting Possibilities in AI-Driven Drug Discovery as Wet-Lab Partner for Latent-X2 Innovation
real-world drug candidates with unprecedented speed and precision.""GenScript is dedicated to catalysing the next generation of AI-first biotechnology," said Dr. Ray Chen, President of GenScript Life Science Group. "With the launch of Latent-X2, we are demonstrating how high-throughput wet-lab
More news about: GenScript Biotech Corporation
Jan 28, 2026, 08:30 ET Subsidiary of Pinnacle Food Group Limited Enters into Biotechnology Research Collaboration Agreement
subsidiary, Pinnacle Food AgTech HK Limited, has entered into a research and technology collaboration agreement with Bioboost Synbio Consulting Inc., a biotechnology consulting company based in Vancouver, Canada.
More news about: Pinnacle Food Group Limited
Jan 28, 2026, 07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease
improving the bioavailability of small-molecule drugs.A Nano-Scale "Medicinal Guide": Reimagining Curcumin with Modern BiotechnologyAcademician Dr. Lin Jaung-Geng of Academia Sinica explained that curcumin, long revered in traditional medicine as a "food-medicine homolog,"
More news about: China Medical University Hospital
Jan 28, 2026, 07:30 ET REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
which has been shown to correlate with neurocognitive manifestations of the disorder.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jan 28, 2026, 06:30 ET Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Jan 28, 2026, 06:00 ET Danaher Reports Fourth Quarter and Full Year 2025 Results
December 31, 2025 ($14 million pretax as reported in this line item, $11 million after-tax), technology, other intangible assets and a facility in the Biotechnology segment recorded in the year ended December 31, 2025 ($101 million pretax as reported in this line item, $69 million after-tax), a trade name in
More news about: Danaher Corporation
Jan 28, 2026, 05:30 ET First Mold's U.S. Mold Exports Rise 30% in 2025, Driven by Electronics, Automotive, and Medical Manufacturing Demand
9.8 %Medical and biotechnology8.5 %
More news about: First Mold